INK4A methylation even though both genes physically overlap. None of the target genes was methylated in the normal brain samples. In addition, the p53 gene was mutated in 19 out of 85 (22%) samples as determined by single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Thirty out of 85 (35%) brain tumors had either a p53 mutation or methylation of p14 ARF . Also, the p14 ARF expression in p53 wild-type gliomas was lower than levels in p53 mutated gliomas. This finding is consistent with wild-type p53 being able to autoregulate its levels by downregulating expression of p14 ARF . In summary, inactivation of the apoptosis pathway that included the p14 ARF and p53 genes by hypermethylation and mutation, respectively, occurred frequently in human brain tumors. Down-regulation of p14 ARF in gliomas was associated with hypermethylation of its promoter and the presence of a wild-type p53 in these samples.
ARF and retinoblastoma (RB) genes was studied using methylation specific polymerase chain reaction (MSP) in 85 human brain tumors of various subtypes and four normal brain samples. These genes play an important role in the control of the cell cycle. Twenty-four out of 85 cases (28%) had at least one of these genes methylated. The frequency of p14 ARF methylation was 15 out of 85 (18%) cases, and the expression of p14 ARF in methylated gliomas was significantly lower than in unmethylated gliomas. The incidence of methylation of p15 INK4B , p16 INK4A and RB gene was 4%, 7%, and 4%, respectively. Samples with p14 ARF methylation did not have p16
INK4A methylation even though both genes physically overlap. None of the target genes was methylated in the normal brain samples. In addition, the p53 gene was mutated in 19 out of 85 (22%) samples as determined by single strand conformation polymorphism (SSCP) analysis and DNA sequencing. Thirty out of 85 (35%) brain tumors had either a p53 mutation or methylation of p14 ARF . Also, the p14 ARF expression in p53 wild-type gliomas was lower than levels in p53 mutated gliomas. This finding is consistent with wild-type p53 being able to autoregulate its levels by downregulating expression of p14 ARF . In summary, inactivation of the apoptosis pathway that included the p14 Introduction A number of genes are mutated in human brain tumors (Louis, 1994; Nishikawa et al., 1995; Duerr et al., 1998) . Chromosome region 9p21, containing the p16 INK4A , p15 INK4B and p14 ARF genes, is involved in inversions, translocations, and heterozygous and homozygous deletions in a variety of tumors and malignant cell lines including gliomas (Liu et al., 1995a,b; Igaki et al., 1994; Ogawa et al., 1994; Kamb et al., 1994a; Nobori et al., 1994; Cairns et al., 1994 Cairns et al., , 1995 Caldas et al., 1994; Bartsch et al., 1995; Hussussian et al., 1994; Ranade et al., 1995; Kamb et al., 1994b) . p16 INK4A and p15 INK4B are tumor suppressors that induce a G1 cell cycle arrest by inhibiting the activity of cyclin dependent kinases 4 and 6 (CDK4 and CDK6) to phosphorylate the RB protein (Lukas et al., 1995; Koh et al., 1995; Serrano et al., 1993; Hannon and Beach, 1994) . These two genes and p14 ARF are in close proximity to each other. In fact, p16
INK4A and p14 ARF share exons 2 and 3, but have entirely different reading frames (Duro et al., 1996; Mao et al., 1995; Quelle et al., 1995; Stott et al., 1998) (Figure 1 ).
Besides alteration in structure, tumor suppressor genes can also be inactivated by epigenetic changes. Hypermethylation of CpG islands within the promoter region is one of the mechanisms by which tumor suppressor genes can be silenced. Methylation of p16 INK4A , p15 INK4B and p14 ARF as well as the RB gene, has been reported in several types of tumors and cell lines (Simpson et al., 2000; Merlo et al., 1995; Costello et al., 1996; Esteller et al., 2000; Stirzaker et al., 1997; Sakai et al., 1991; Ohtani-Fujita et al., 1997; Schmidt et al., 1997; Watanabe et al., 2001; Robertson and Jones, 1998; Nakamura et al., 2001a,b) .
The MDM2 protein binds and causes the degradation of p53 (Zhang et al., 1998) . The p14 ARF binds to MDM2 and promotes the rapid degradation of MDM2 (Zhang et al., 1998) . Wild-type p53 can down-regulate expression of p14 ARF , establishing an autoregulatory feedback loop between p53, MDM2 and p14 ARF (Stott et al., 1998; Robertson and Jones, 1998) (Figure 1 ).
In this study, we performed a very large, detailed analysis of the methylation status of key genes involved in the cell cycle using the methylation specific polymerase chain reaction (MSP) on genomic DNA from 85 brain tumors and four normal brain samples. In addition, expression levels of p14 ARF were compared to the methylation status of the gene. Also, genomic integrity of the p53 gene was examined in all the samples. (Figure 1) . Methylation of these genes can prevent their normal expression. We examined the methylation status of all four of these genes in 85 brain tumors and four normal brain samples. Twentyfour out of 85 cases (28%) had at least one of these genes methylated (Figure 2 ). The methylation frequency of the p14 ARF , p15 INK4B , p16 INK4A and RB genes was 18%, 4%, 7%, and 4%, respectively. In contrast, methylation of these genes did not occur in any of the four normal brain samples. Twenty-four per cent of gliomas, 32% of meningiomas, 40% of other types of brain tumors (ependymomas, schwannomas, craniopharyngiomas, chordomas, hemangiomas, medulloblastomas) had at least one of these genes methylated. Concerning glioma samples, p16
Results

Methylation
INK4A was methylated only in GBMs (Table 1 ; Figure 2 ). The frequency of methylation of p14 ARF did not correlate with the grade of the tumor (Table 1) . Promoter hypermethylation of the p14 ARF gene was independent of the methylation status of p16 INK4A even though their promoters are very close to each other on 9p21 and they share two exons, albeit in a different reading frame (Table 1 , Figures 1 and 2 ). In some samples, no PCR products were detected by MSP, suggesting a possible homozygous deletion of the gene (Figure 2 ).
p53 gene mutations
We examined the p53 gene for mutations in exons 5 -8 by SSCP (Figure 3 ). Twenty-two mutations occurred in 19 out of the 85 brain tumor samples (Table 1) , including 20 missense mutations and two insertions; three samples had two mutations per sample. Most p53 mutations occurred in gliomas, especially in individuals , Rb, and p53 (Stott et al., 1998; Robertson and Jones., 1998; Sherr 1996) . The overlapping regions of p14 ARF and p16 INK4A (exons 2 and 3) use different reading frames. CDK4/6, cyclin dependent kinases 4 and 6, E2F, transcription factor who were less than 50 years of age (chi-square test, P50.05, 
in glioma samples
Methylation of a gene might be expected to result in reduction of its expression. Indeed, we found that the expression of p14 ARF in the nine glioma samples with a methylated p14 ARF promoter was significantly lower (mean value, 1.0) than that in 31 randomly selected glioma samples with an unmethylated p14 ARF (mean value, 5.7) (Student's t-test, P50.05, Figure 4a ).
Wild-type p53 associated with low levels of p14 ARF expression Expression of p14 ARF was studied by real-time PCR in the gliomas, including the 15 samples with mutation of p53 and 25 samples with a wild-type p53. Expression of p14 ARF in samples with a p53 mutation was much higher (mean value, 3.4) than in those with a wild-type p53 (mean value, 1.0) (Figure 4b ). For example, 19 out of 25 glioma samples with a wild-type p53 had very low expression of p14 ARF (mean value 50.5). In contrast, only five out of 15 glioma samples with a mutant p53 had a similarly low p14 ARF expression level (chi-square test, P50.05). These results were consistent with wild-type p53 down-regulating p14 ARF expression.
Discussion
The p14 ARF , p15 INK4B , p16 INK4A and RB all behave as tumor suppressor genes and their loss of expression contributes to the development of cancer. Methylation of these genes is one mechanism for their loss of expression in human cancers (Simpson et al., 2000; Merlo et al., 1995; Costello et al., 1996; Esteller et al., 2000 Stirzaker et al., 1997 Sakai et al., 1991; OhtaniFujita et al., 1997; Greger et al., 1994; Nishikawa et al., 1995) . We found that p15 INK4B , p16
INK4A and RB genes were methylated 4%, 7%, and 4%, respectively. The frequency of methylation of p16 INK4A in gliomas has previous been reported to be 24% irrespective of their tumor grade (Costello et al., 1996) . In our study, p16
INK4A was methylated in 6% of gliomas; and each of these cases was a GBM. p15 INK4B and p16
INK4A
induce G1 cell cycle arrest by inhibiting the ability of the cyclin dependent kinases, CDK4 and CDK6 to phosphorylate RB (Serrano et al., 1993; Sherr, 1996) . The p15 INK4B and p16 INK4A proteins are encoded by the highly homologous CDKN2B and CDKN2A genes, respectively (Kamb et al., 1994b; Jen et al., 1994; Hannon and Beach, 1994; Guan et al., 1994) . Therefore, disruption of both p15 INK4B and p16
theoretically might be required to lead to a prominent growth advantage for a tumor cell (Simon et al., 1999) . We found that no sample had methylation of both p15 INK4B and p16 INK4A genes, and only 4% of samples had methylation of RB. Taken together, the relatively low frequency of methylation of p15 INK4B , p16 INK4A and RB genes suggests that methylation of these growth control genes does not play a major role in the development of a majority of brain tumors. The p53 gene is directly altered in about 50% of human cancers (Hainaut et al., 1997) . The p53 pathway in tumors having a wild-type p53 can, nevertheless, be aberrant. For example, MDM2 over-expression can (40) 6 (15%) 1 (3%) 2 (5%) 3 (8%) 3 (8%) 4 50 years of age (45) 9 (20%) 2 (4%) 4 (9%) 0 16 (36%)
Only glioma samples GBMs (30) 4 (13%) 1 (3%) 3 (10%) 0 7 (23%) Astrocytomas (14) 3 (21%) 0 0 0 6 (43%) Oligodendrogliomas (7) 2 (29%) 1 (14%) 0 0 3 (43%) Males (32) 7 (22%) 1 (3%) 3 (9%) 0 11 (34%) Females (19) 2 (11%) 1 (5%) 0 0 6 (32%) 4 50 years of age (22) 2 (9%) 0 2 (9%) 0 3 (14%) 4 50 years of age (29) 7 (24%) 2 (7%) 1 (3%) 0 13 (45%) a : Other brain tumors: ependymomas, schwannomas, craniopharyngiomas, chordomas, hemangiomas, medulloblastomas Figure 3 Representative analysis of the mutation status of exon 5 of the p53 gene in brain tumors using single strand conformation polymorphism (SSCP). The shifted bands shown by arrows indicate the mutant p53. Numbers represent case identifiers lead to rapid degradation of the p53 protein (Stott et al., 1998; Zhang et al., 1998 , Kamijo et al., 1998 Pomerantz et al., 1998; Prives, 1998) . The p14 ARF protein binds to the p53/MDM2 complex and inhibits MDM2-mediated degradation of p53, which indicates that p14 ARF is an upstream regulator of p53 via MDM2 (Stott et al., 1998; Zhang et al., 1998; Pomerantz et al., 1998; Kamijo et al., 1998; Tao and Levine, 1999) . Aberrant p14 ARF results in elevated levels of MDM2 and lower levels of p53. We found the frequency of p14 ARF methylation was 18%. Furthermore, we showed that methylation of the p14 ARF promoter was associated with reduced expression of p14 ARF in gliomas. A study of brain cancers in general, also came to a similar conclusion (Nakamura et al., 2001a) . We found a 22% frequency of p53 mutations in brain tumors. Together, 30 out of a total of 85 cases (35%) had either a p14 ARF methylation, a p53 mutation, or both. Thus, alteration of this pathway is frequently associated with the development of brain tumors.
In one study, p14 ARF could only be detected in cell lines that had a defective p53 gene (Stott et al., 1998) . Activation of wild-type p53 was associated with a markedly decreased expression of p14 ARF (Stott et al., 1998) . Furthermore, p14
ARF promoter reporter gene studies showed that wild-type p53 markedly decreased p14 ARF promoter reporter gene activity (Robertson and Jones, 1998) . In contrast, transfection of increasing amounts of mutant p53 increased the activity of the p14 ARF promoter (Robertson and Jones, 1998) . Taken together, these studies suggest an autoregulatory feedback loop between p53, MDM2 and p14 ARF (Robertson and Jones, 1998; Stott et al., 1998) . To date, most of these studies have used cell lines. We show in clinical glioma samples for the first time, that most glioma samples with p53 mutations have a higher level of expression of p14 ARF than those samples with wild-type p53. The pathologic significance of these findings requires further study.
In summary, the frequency of methylation of the p14 ARF , p15 INK4B , p16 INK4A , and RB genes was 18%, 4%, 7% and 4%, respectively. The methylation of p14 ARF occurred independently of p16 INK4A methylation in brain tumors even though the two genes physically overlap with each other on 9p21. The expression of p14 ARF was decreased in samples with methylation of their promoters. Also, p14 ARF levels were usually higher in those samples having a p53 mutation, possibly because wild-type p53 can decrease transcription of p14 ARF . The frequency of brain tumors having a p53 mutation and/or p14 ARF methylation was 35%, suggesting that aberration of this pathway plays an important role in development of brain cancers; and therapies should be directed at this pathway.
Materials and methods
Tumor samples
We studied eighty-five brain tumor samples: seven oligodendrogliomas, 14 astrocytomas, 30 GBMs, 19 meningiomas, two ependymomas, four schwannomas, three craniopharyngiomas, two chordomas, three hemangiomas, and one medulloblastoma, as well as four normal brain samples. All samples were obtained at the time of surgery after the pathology specimens had been obtained. Each was quick frozen in liquid nitrogen and stored at 7708C until they were processed.
DNA isolation and MSP
DNA was isolated by QIAamp DNA Mini-kit (QIAGEN Inc. Valencia, CA, USA). MSP was performed as previously described (Herman et al., 1996) . 1 mg DNA was treated with (Simpson et al., 2000; Esteller et al., 2000; Herman et al., 1996) . CpGenome TM Universal Methylated DNA (Intergen) was used as the positive control for methylated genes, and DNA from normal peripheral blood mononuclear cells was employed as the control for unmethylated genes. H 2 O was utilized as blank control.
Detection of p53 mutations
Presence of p53 gene mutations was detected by single strand conformation polymorphism (SSCP), and all aberrantly migrating bands were DNA sequenced. For SSCP, the PCR reaction contained 20 ng DNA, 500 nM of each of the primers, 200 nM of each of the dNTP, 0.5 units of Taq DNA polymerase and 3 uCi [a-32 P] dCTP in 20 ml. PCR products were diluted 10-fold in the loading buffer containing 10 mM NaOH, 95% formamide, and 0.05% of both bromophenol blue and xylene cyanol. After denaturation at 948C for 5 min, 2 ml of the samples were loaded onto a 6% nondenaturating polyacrylamide mutation detection enhancement gel (MDE, Bioproducts, Rockland, ME, USA) with 10% (v/v) glycerol and separated at 4 -6 W for 20 h. Subsequently, the gel was dried and subjected to autoradiography. The p53 gene was analysed for mutations in exons 5 -8 which encompasses the region that is most frequently mutated (Imai et al., 1994) . Single-strand with nucleotide polymorphism variant showed a distinct migration pattern in SSCP analysis. Shifted bands were excised and eluted by diffusion in 50 ml TE buffer. One microlitre of TE eluate was used as template to reamplify the fragment. The resulting product was sequenced using the ABI PRISM dye terminator cycle sequencing reaction (PerkinElmer, Forster, CA, USA).
RNA isolation and RT -PCR
Extraction of total RNA was carried out using Trizol reagent (Life Technologies, Inc. Grand Island, NY, USA) according to the manufacturer's instructions. Approximately 2 mg of RNA was reverse-transcribed with random primers (Life Technologies Inc.) and Superscript TM II reverse transcriptase (Life Technologies Inc.). The cDNA was used for real-time PCR.
Real-time PCR
Theoretical basis Reactions were characterized at the point during cycling when amplification of the PCR product was first detected, rather than measuring the amount of PCR product accumulated after a fixed number of cycles. The parameter C t (threshold cycles) was defined as the fractional cycle number at which the fluorescence generated by cleavage of the probe passes a fixed threshold above baseline. The p14 ARF target message in unknown samples was quantified by measuring C t and by using a standard curve to determine the quantity of starting target message. We also quantified transcripts of beta-actin as the endogenous control, and each sample was normalized on the basis of its beta-actin content. For each experimental sample, the amount of the target and endogenous reference was determined from the standard curve. The target amount was divided by the endogenous reference amount to obtain a normalized target value. The relative expression level of target was also normalized to a calibrator (mean value). We selected the mean value of samples with methylation in Figure 4a and mean value of samples with wild-type p53 in Figure 4b as (http://www-genome.wi.mit.edu/cgibin/primer/ primer3www.cgi) according to the nucleotide sequences of Genebank accession number U38945: Forward primer, 5'-CTACTGAGGAGCCAGCGTCT; reverse primer, 5'-CACGGGTCAGGTGAGAGTG; probe, 5'-CTGCCCAT-CATCATGACCTGGTCTT. Forward primer was on exon 1, and reverse primer was on exon 2. Real-time PCR was performed in reaction buffer TaqMan Universal PCR Master Mix, 100 nM probe and 300 nM primers in a total volume of 25 ul. After a denaturation step of 10 min at 958C, two-step amplification conditions were 50 cycles of 15 s at 958C, 60 s at 608C. Amplification and product detection were performed with an iCycler iQ TM system (Bio-Rad, Hercules, CA, USA). We used the b-actin cDNA to normalize the expression data of p14 ARF . Primers and probe of b-actin were: 5'-TCCCTGGAGAAGAGCTACGA (forward), 5'-AGGAAG-GAAGGCTGGAAGAG (reverse), 5'-CAATGAGCGGTT-CCGCTGCC (probe). All experiments were done in triplicate. The variance of threshold cycle value between the triplicates was 55%. The values of copy number of p14 ARF cDNA were used to determine relative expression of p14 ARF . The copy number of p14 ARF cDNA in brain tissue samples was calculated from the p14 ARF standard curve of real-time PCR and normalized to the copy number of b-actin in each sample.
